ReviewParticle and fibre toxicology2025
Biopersistence of man-made vitreous fibres (MMVF) / synthetic vitreous fibres (SVF): advancing from animal models to acellular testing.
Review in Particle and fibre toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of fibre toxicology highlights a significant connection between the physicochemical properties of fibres-such as diameter, length, and durability-and their toxicity when inhaled. Among these properties, durability, particularly in terms of biopersistence and retention time in the lungs, is crucial in determining chronic toxicity. This understanding of fibre biopersistence is especially relevant to the regulation and safety assessment of Man-Made Vitreous Fibres (MMVF), also referred to in North American literature as Synthetic Vitreous Fibres (SVF). Despite its importance, current practices rely heavily on in vivo testing methods for evaluating biopersistence, which conflicts with the movement towards reducing animal testing and utilising new approach methodologies (NAMs) for hazard and risk assessment. In vitro assessments of biodurability have long been employed by the research community and industry alike to investigate the persistence of fibres in the lung, offering an alternative to reduce animal testing to evaluate this critical mediator of fibre toxicity. Here, we explore recent developments in acellular in vitro biodurability approaches for assessing fibre durability in the lung, addressing the variations and key challenges associated with using these methods to determine the safety of bio-soluble MMVF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.